1-20 of 25
Jorge Cortes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia

Xuejie Jiang, Po Yee Mak, Hong Mu, Wenjing Tao, Duncan H. Mak, Steven Kornblau, Qi Zhang, Peter Ruvolo, Jared K. Burks, Weiguo Zhang, Teresa McQueen, Rongqing Pan, Hongsheng Zhou, Marina Konopleva, Jorge Cortes, Qifa Liu, Michael Andreeff, Bing Z. Carter
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (10): 2417–2429.
https://doi.org/10.1158/1078-0432.CCR-17-1556
Published: 14 May 2018
View article titled, Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <em>FLT3</em>-Mutant Acute Myeloid Leukemia
Open the PDF for Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <em>FLT3</em>-Mutant Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract 16: Genomic landscape of adult mixed phenotype acute leukemia (MPAL)

Koichi Takahashi, Feng Wang, Kiyomi Morita, Keyur Patel, Carlos Bueso-Ramos, Abdallah Abou Zahr, Curtis Gumbs, Latasha Little, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Jianhua Zhang, Xingzhi Song, Marisela Mendoza, Chang-Jiu Wu, Steven Kornblau, Courtney DiNardo, Guillermo Garcia-Manero, Elias Jabbour, Michael Andreeff, Farhad Ravandi, Hagop Kantarjian, Jorge Cortes, Marina Konopleva, Andrew Futreal
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 16.
https://doi.org/10.1158/1557-3265.HEMMAL17-16
Published: 14 December 2017
View article titled, Abstract 16: Genomic landscape of adult mixed phenotype acute leukemia (MPAL)
Journal Articles

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

Lina Han, Jeffrey L. Jorgensen, Chris Brooks, Ce Shi, Qi Zhang, Graciela M. Nogueras González, Antonio Cavazos, Rongqing Pan, Hong Mu, Sa A. Wang, Jin Zhou, Gheath AI-Atrash, Stefan O. Ciurea, Mike Rettig, John F. DiPersio, Jorge Cortes, Xuelin Huang, Hagop M. Kantarjian, Michael Andreeff, Farhad Ravandi, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (13): 3385–3395.
https://doi.org/10.1158/1078-0432.CCR-16-1904
Published: 02 July 2017
View article titled, Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
Open the PDF for Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Naval Daver, Yanis Boumber, Hagop Kantarjian, Farhad Ravandi, Jorge Cortes, Michael E. Rytting, Jitesh D. Kawedia, Jordan Basnett, Kirk S. Culotta, Zhihong Zeng, Hongbo Lu, Mary Ann Richie, Rebecca Garris, Lianchun Xiao, Wenbin Liu, Keith A. Baggerly, Elias Jabbour, Susan O'Brien, Jan Burger, Linda J. Bendall, Deborah Thomas, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2704–2714.
https://doi.org/10.1158/1078-0432.CCR-14-2888
Published: 14 June 2015
View article titled, A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Open the PDF for A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome

Wanlong Ma, Hagop Kantarjian, Benjamin Bekele, Amber C. Donahue, Xi Zhang, Zhong J. Zhang, Susan O'Brien, Elihu Estey, Zeev Estrov, Jorge Cortes, Michael Keating, Francis Giles, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (11): 3820–3826.
https://doi.org/10.1158/1078-0432.CCR-08-3034
Published: 01 June 2009
View article titled, Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome
Open the PDF for Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome in another window
Includes: Supplementary data
Journal Articles

Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia

Alfonso Quintás-Cardama, Jorge Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4392–4399.
https://doi.org/10.1158/1078-0432.CCR-08-0117
Published: 15 July 2008
View article titled, Therapeutic Options Against <em>BCR-ABL1</em> T315I-Positive Chronic Myelogenous Leukemia
Open the PDF for Therapeutic Options Against <em>BCR-ABL1</em> T315I-Positive Chronic Myelogenous Leukemia in another window
Journal Articles

Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

Srdan Verstovsek, Ayalew Tefferi, Jorge Cortes, Susan O'Brien, Guillermo Garcia-Manero, Animesh Pardanani, Cem Akin, Stefan Faderl, Taghi Manshouri, Deborah Thomas, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3906–3915.
https://doi.org/10.1158/1078-0432.CCR-08-0366
Published: 16 June 2008
View article titled, Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Open the PDF for Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis in another window
Journal Articles

The Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients

Apostolia-Maria Tsimberidou, Hagop M. Kantarjian, Sijin Wen, Susan O'Brien, Jorge Cortes, William G. Wierda, Charles Koller, Sherry Pierce, Mark Brandt, Emil J. Freireich, Michael J. Keating, Elihu H. Estey
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 721–730.
https://doi.org/10.1158/1078-0432.CCR-07-2063
Published: 01 February 2008
View article titled, The Prognostic Significance of Serum β<sub>2</sub> Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients
Open the PDF for The Prognostic Significance of Serum β<sub>2</sub> Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients in another window
Journal Articles

WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation

Srdan Verstovsek, Taghi Manshouri, Alfonso Quintás-Cardama, David Harris, Jorge Cortes, Francis J. Giles, Hagop Kantarjian, Waldemar Priebe, Zeev Estrov
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 788–796.
https://doi.org/10.1158/1078-0432.CCR-07-0524
Published: 01 February 2008
View article titled, WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation
Open the PDF for WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation in another window
Journal Articles

Important Therapeutic Targets in Chronic Myelogenous Leukemia

Hagop M. Kantarjian, Francis Giles, Alfonso Quintás-Cardama, Jorge Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1089–1097.
https://doi.org/10.1158/1078-0432.CCR-06-2147
Published: 22 February 2007
View article titled, Important Therapeutic Targets in Chronic Myelogenous Leukemia
Open the PDF for Important Therapeutic Targets in Chronic Myelogenous Leukemia in another window
Journal Articles

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

Francis Giles, Thomas Fischer, Jorge Cortes, Guillermo Garcia-Manero, Joachim Beck, Farhad Ravandi, Eric Masson, Patricia Rae, Glen Laird, Sunil Sharma, Hagop Kantarjian, Margaret Dugan, Maher Albitar, Kapil Bhalla
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4628–4635.
https://doi.org/10.1158/1078-0432.CCR-06-0511
Published: 09 August 2006
View article titled, A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7817–7824.
https://doi.org/10.1158/1078-0432.CCR-05-1070
Published: 08 November 2005
View article titled, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Open the PDF for Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia in another window
Journal Articles

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Karen W.L. Yee, Anne Hagey, Srdan Verstovsek, Jorge Cortes, Guillermo Garcia-Manero, Susan M. O'Brien, Stefan Faderl, Deborah Thomas, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Maher Albitar, Evelyn McKeegan, David R. Grimm, Toby Mueller, Rhonda R. Holley-Shanks, Leonardo Sahelijo, Gary B. Gordon, Hagop M. Kantarjian, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6615–6624.
https://doi.org/10.1158/1078-0432.CCR-05-0650
Published: 15 September 2005
View article titled, Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia

Moshe Talpaz, Ashok Rakhit, Karen Rittweger, Susan O'Brien, Jorge Cortes, Scott Fettner, Leon Hooftman, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6247–6255.
https://doi.org/10.1158/1078-0432.CCR-05-0882
Published: 06 September 2005
View article titled, Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia
Open the PDF for Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia in another window
Journal Articles

AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

Mirna Golemovic, Srdan Verstovsek, Francis Giles, Jorge Cortes, Taghi Manshouri, Paul W. Manley, Jürgen Mestan, Margaret Dugan, Leila Alland, James D. Griffin, Ralph B. Arlinghaus, Tong Sun, Hagop Kantarjian, Miloslav Beran
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (13): 4941–4947.
https://doi.org/10.1158/1078-0432.CCR-04-2601
Published: 06 July 2005
View article titled, AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has <em>In vitro</em> Activity against Imatinib-Resistant Chronic Myeloid Leukemia
Open the PDF for AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has <em>In vitro</em> Activity against Imatinib-Resistant Chronic Myeloid Leukemia in another window
Journal Articles

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Jorge Cortes, Moshe Talpaz, Susan O'Brien, Dan Jones, Rajyalakshmi Luthra, Jenny Shan, Francis Giles, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, Mary B. Rios, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3425–3432.
https://doi.org/10.1158/1078-0432.CCR-04-2139
Published: 02 May 2005
View article titled, Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Open the PDF for Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate in another window
Journal Articles

Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

Jorge Cortes, Deborah Thomas, Charles Koller, Francis Giles, Elihu Estey, Stefan Faderl, Guillermo Garcia-Manero, David McConkey, Gira Patel, Roberto Guerciolini, John Wright, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3371–3376.
https://doi.org/10.1158/1078-0432.CCR-03-0508
Published: 24 May 2004
View article titled, Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias
Open the PDF for Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias in another window
Journal Articles

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

Francis Giles, Deborah Thomas, Guillermo Garcia-Manero, Stefan Faderl, Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli, Sima Jeha, Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill, Caroline Clairmont, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 2908–2917.
https://doi.org/10.1158/1078-0432.CCR-03-0738
Published: 06 May 2004
View article titled, A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Open the PDF for A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia in another window
Journal Articles

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

Hagop Kantarjian, Susan O’Brien, Jorge Cortes, Francis Giles, Jianqin Shan, Mary Beth Rios, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Michael Keating, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 68–75.
https://doi.org/10.1158/1078-0432.CCR-1035-3
Published: 20 January 2004
View article titled, Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
Open the PDF for Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls in another window
Journal Articles

Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia

Hagop M. Kantarjian, Moshe Talpaz, Jorge Cortes, Susan O’Brien, Stefan Faderl, Deborah Thomas, Francis Giles, Mary Beth Rios, Jianqin Shan, Ralph Arlinghaus
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 160–166.
Published: 01 January 2003
View article titled, Quantitative Polymerase Chain Reaction Monitoring of <em>BCR-ABL</em> during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia
Open the PDF for Quantitative Polymerase Chain Reaction Monitoring of <em>BCR-ABL</em> during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia in another window